Latest news and press releases about Absci Corporation (ABSI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States.
Price
| Price | $8.04 |
| Market Cap | $1.4B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.74 |
| EV / EBITDA | -11.70 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -59.21% |
| Return on Invested Capital | -52.24% |
| Return on Assets | -45.02% |
| Gross Margin | -255.93% |
| Operating Margin | -8411.27% |
| Net Margin | -7756.37% |
Related companies: CRVS · ERAS · GOSS · MGTX · MLTX · OLMA · PRTA
Explore sector: Healthcare · Biotechnology
More sections of ABSI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks